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Abstract: Statins reduce cardiovascular morbidity and mortality. These beneficial effects are not fully
explained by their lipid-lowering action. As such, we investigated the impact of a new statin, rosu-
vastatin, on endothelial function, the key event in early atherogenesis, in an experimental model of
normocholesterolemic hypertension. Hypertension was induced in Wistar-Kyoto rats by inhibition of
11￿-hydroxysteroid dehydrogenase type 2 (11￿-HSD2) with Glycyrrhizic acid (GA). 11￿-HSD2 provides
mineralocorticoid receptor specificity for aldosterone by metabolising glucocorticoids to their receptor
inactive 11-dehydro derivatives. GA was added to the drinking water (3 g/L) for 21 days. From days 8 to
21 rosuvastatin (20 mg/kg/d) or placebo were added to chow. Endothelium-dependent and -independent
relaxation of isolated aortic rings to acetylcholine (ACh, 10-10-10-5 mol/L) and sodium nitroprusside
(SNP, 10-10-10-5 mol/L) was measured. In addition, vascular reactivity to endothelin-1 (ET-1; 10-10-10-
7 mol/L) was investigated. ETA and ETB receptor mRNA expression was determined by RT-PCR and
RhoA activity by a pull-down assay. Systolic blood pressure increased in rats treated with GA (175 vs 153
mmHg in controls; p<0.01). Endothelium-dependent relaxations to acetylcholine were blunted after GA
treatment (p￿0.005 vs control), while the responses to SNP remained unchanged. Rosuvastatin normalized
NO-mediated endothelium-dependent relaxation in hypertensive animals (p￿0.01 vs placebo), although
blood pressure and cholesterol levels were not affected by the statin. Vascular reactivity to ET-1 was
increased by GA (p<0.01 vs control), but not affected by rosuvastatin. ETB receptor mRNA decreased
in the GA group (p<0.05 vs control) and was upregulated by rosuvastatin (p<0.005; GA+rosuvastatin vs
GA), whereas ETA receptor mRNA upregulation in the GA group (p<0.01 vs control) was partially pre-
vented by the statin. In addition, GA increased Rho-GTP binding (p￿0.05 vs control) which was prevented
in both groups by rosuvastatin treatment (p￿0.01 control+rosuvastatin vs control and GA+rosuvastatin
vs GA). These data for the first time show that HMG-CoA inhibition improves endothelial dysfunction
in normocholesterolemic mineralocorticoid hypertension without affecting blood pressure or cholesterol
levels by correction of a stimulated endothelin system
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beneficial synergistic effects upon the blood pressure as well as the
vasculature.
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HMG-COA REDUCTASE INHIBITOR IMPROVES
ENDOTHELIAL DYSFUNCTION IN
MINERALOCORTICOID HYPERTENSION BY
INHIBITION OF RHOA
Matthias Hermann, Frank Ruschitzka, Giovanni Camici, Sidney Shaw,
Thomas F Luscher. Cardiovascular Research, University Zurich-
Irchel, Zurich, Switzerland; Cardiovascular Center, University
Hospital, Zurich, Switzerland; Department of Clinical Research,
Inselspital Bern, Bern, Switzerland.
Statins reduce cardiovascular morbidity and mortality. These beneficial
effects are not fully explained by their lipid-lowering action. As such, we
investigated the impact of a new statin, rosuvastatin, on endothelial
function, the key event in early atherogenesis, in an experimental model
of normocholesterolemic hypertension.
Hypertension was induced in Wistar-Kyoto rats by inhibition of 11-
hydroxysteroid dehydrogenase type 2 (11-HSD2) with Glycyrrhizic
acid (GA). 11-HSD2 provides mineralocorticoid receptor specificity for
aldosterone by metabolising glucocorticoids to their receptor inactive
11-dehydro derivatives. GA was added to the drinking water (3 g/L) for
21 days. From days 8 to 21 rosuvastatin (20 mg/kg/d) or placebo were
added to chow. Endothelium-dependent and -independent relaxation of
isolated aortic rings to acetylcholine (ACh, 10-10-10-5 mol/L) and sodium
nitroprusside (SNP, 10-10-10-5 mol/L) was measured. In addition, vascu-
lar reactivity to endothelin-1 (ET-1; 10-10-10-7 mol/L) was investigated.
ETA and ETB receptor mRNA expression was determined by RT-PCR
and RhoA activity by a pull-down assay. Systolic blood pressure in-
creased in rats treated with GA (175 vs 153 mmHg in controls; p0.01).
Endothelium-dependent relaxations to acetylcholine were blunted after
GA treatment (p0.005 vs control), while the responses to SNP re-
mained unchanged. Rosuvastatin normalized NO-mediated endothelium-
dependent relaxation in hypertensive animals (p0.01 vs placebo),
although blood pressure and cholesterol levels were not affected by the
statin. Vascular reactivity to ET-1 was increased by GA (p0.01 vs
control), but not affected by rosuvastatin. ETB receptor mRNA decreased
in the GA group (p0.05 vs control) and was upregulated by rosuvastatin
(p0.005; GArosuvastatin vs GA), whereas ETA receptor mRNA
upregulation in the GA group (p0.01 vs control) was partially pre-
vented by the statin. In addition, GA increased Rho-GTP binding
(p0.05 vs control) which was prevented in both groups by rosuvastatin
treatment (p0.01 controlrosuvastatin vs control and
GArosuvastatin vs GA).
These data for the first time show that HMG-CoA inhibition improves
endothelial dysfunction in normocholesterolemic mineralocorticoid hy-
pertension without affecting blood pressure or cholesterol levels by
correction of a stimulated endothelin system.
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PLASMA IMMUNOREACTIVE ENDOTHELIN-1
LEVELS IN HYPERTENSIVE RATS AND HUMAN
SUBJECTS
Saad Abdel-Sayed, Peter Gohlke, Hans R Brunner, Juerg Nussberger.
University Hospital CHUV, Division of Hypertension, Lausanne, Vaud,
Switzerland.
Endothelin-1 (ET-1) is an endothelium-derived potent vasoconstrictor
peptide of 21 amino acids. To establish reference values in different
forms and models of hypertension and in human subjects an assay for
plasma ET-1 was optimized. Immunoreactive (ir-) ET-1 is extracted by
acetone from 1 ml plasma and subjected to a sensitive sandwich type
enzyme linked immunosorbent assay. The detection limit for plasma
ET-1 (3 SD above zero readings) is 0.05 fmol/ml. Mean recoveries of the
1, 2, 5, 10 fmol of ET-1 added to 1 ml plasma (n  5, each) were 66, 75,
85 and 92 % respectively. The within-assay coefficients of variation were
12, 5, 3, 3 and 0.5 % for plasma ET-1 concentrations of 0.84, 1.5, 2.3, 5.2
and 9.9 fmol/ml respectively. Between-assay coefficients of variation for
two human control plasmas containing 1.0 fmol/ml (n  8) and 1.2
fmol/ml ET-1 (n  7) were 8% and 10% respectively. Assay accuracy
was demonstrated by the consistent recoveries of added ET-1 and by the
linearity of ir-ET-1 concentrations measured in serially diluted plasma
extracts (r  0.99). No ir-ET-1 was detected when albumin buffer was
extracted instead of plasma (buffer blank). Using this method, we found
increased ir-ET-1 levels in plasma of three experimental rat models of
hypertension. (i) Plasma ir-ET-1 concentrations were significantly higher
in stroke-prone spontaneously hypertensive rats (SP-SHR) than in nor-
motensive Wistar rats. (ii) DOCA-salt hypertensive rats exhibited 4 times
higher ir-ET-1 levels than sham operated control rats. (iii) One kidney-
one clip (1K-1C) hypertensive rats showed moderately increased ir-ET-1
levels compared to sham operated controls. In contrast, the ir-ET-1 levels
in plasma of SHR were half that of normotensive Wistar rats. In two
kidney-one clip (2K-1C) Goldblatt hypertensive rats, the plasma ir-ET-1
concentrations were not different from sham-operated control rats. The
plasma ir-ET-1 concentrations of 37 healthy human subjects were 0.85
0.26 fmol/ml (mean  SD). We conclude that the present assay reliably
measures plasma immunoreactive ET-1 levels in rats and in human
subjects. Normal plasma ET-1 concentrations in humans and conscious
rats are in the low picomolar range.
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IDENTIFICATION OF DOMINANT NEGATIVE RAT
RAMPs ABLE TO INHIBIT ENDOGENOUS
ADRENOMEDULLIN RECEPTOR FUNCTION
Kenji Kuwasako, Kazuo Kitamura, Johji Kato, Tanenao Eto. First
Department of Internal Medicine, Miyazaki Medical College, Kiyotake,
Miyazaki, Japan.
Adrenomedullin (AM) exerts a wide variety of biological effects, includ-
ing potent vasorelaxation. Its receptors were recently shown to be het-
erodimers comprised of a novel accessory protein, the receptor activity-
modifying protein (RAMP), and the calcitonin receptor-like receptor
(CRLR). When CRLR is co-transfected with RAMP2 or -3, the two
proteins are transported together to the plasma membrane where they
function as an AM-specific receptor. Recently, we have shown that seven
amino acids of human (h)RAMP2 (86-92) and hRAMP3 (59-65) are
essential for high-affinity agonist binding to hAM receptors. Interest-
ingly, both seven-residue segments are located between three conserved
residues (Trp, Cys and Tyr) and the three ones are common to humans,
rats and mice. In this study, we examined whether seven-residue seg-
ments situated between three residues conserved in both rat (r)RAMP2
and rRAMP3 (amino acids 93-99 and 58-64, respectively) are key
determinants of agonist binding to rAM receptors, and then tested
whether their deletion mutants can act as dominant negative RAMPs.
Control
Ang II
(n  8)
Ang II-AML
(n  7)
SBP (mmHg) 135  2 175  3* 132  6
Body Weight (g) 288  10 261  11** 261  10**
Ao weight (mg/cm) 13.2  0.3 16.9  1.3* 13.4  0.4
O2 (cpm/mg/min) 608  159 1005  140* 595  62
ONOO (cpm/mg/min) 782  115 1875  295* 1142  134
Emax (% of NE contraction) 105  4 86  3* 102  3
ED50 ( Log M) 8.0  0.27 6.6  0.19* 7.6  0.18
* P  0.05 vs Control and Ang II—AML; ** P  0.05 vs Control
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